BTIG analyst Sam Eiber raised the firm’s price target on Establishment Labs (ESTA) to $86 from $81 after applying the 9-times multiple on the firm’s rolled forward 12-24 month revenue estimates. BTIG keeps a Buy rating on the shares. Earlier this week, Establishment Labs announced that it submitted Motiva to the FDA for a label expansion into primary and revision breast reconstruction.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESTA:
- Establishment Labs submits Motiva implants for FDA approval
- Establishment Labs price target raised to $85 from $72 at Canaccord
- Establishment Labs price target raised to $90 from $85 at Mizuho
- Establishment Labs Holdings: Strategic Growth and Profitability Prospects Reinforce Buy Rating
- Establishment Labs price target raised to $75 from $62 at Citi